Business

Kitov Pharmaceuticals is an innovative biopharmaceutical company focused on late-stage drug development. The company’s current product pipeline features two combination drugs intended to treat osteoarthritis (OA) pain and hypertension (HTN) simultaneously. By lowering development risk and cost through streamlined regulatory approval of novel therapeutics, Kitov plans to delivers rapid ROI while making a meaningful impact on people’s lives.

Products

Kitov’s current pipeline products, KIT-301 and KIT-302, are combination drugs that treat OA pain and HTN simultaneously. In December 2015, KIT-302 successfully achieved the primary efficacy endpoint for its Phase III clinical trial. In August 2016, the United States Patent Office issued a patent covering KIT-302.

Market

Of the 27 million Americans with OA, 50% also suffer from HTN, which is also a common side effect of stand-alone OA drugs. With no single medication currently treating both conditions, KIT-301 and KIT-302 are targeting this multi-billion dollar market.

Team

Kitov features a world-caliber team with decades of managerial, entrepreneurial, scientific, medical and financial experience. Chaired by a former FDA medical officer, the Kitov team has a proven track record leveraging deep regulatory and clinical-trial expertise that leads to streamlined end-to-end drug development and approval.

Partnership

Kitov maintains a strategic partnership with Dexcel Pharma, a global pharma company, for providing chemistry, manufacturing and control (CMC) services for KIT-302. Active in 20 countries, Dexcel is involved in the manufacture of 55 drug products. The partnership calls for Dexcel to develop the final formulation of KIT-302, including chemical development, analytical methodology and validation, stability testing, and production of batches for pharmacokinetic studies. Dexcel will also scale-up production for the anticipated new drug application (NDA) submission to the FDA.

Ownership

Founded in 2010, Kitov became a public company in 2013 when its shares were first traded on the Tel Aviv Stock Exchange (TASE). Kitov successfully issued an IPO on NASDAQ in November 2015. The company currently trades on both stock exchanges.